We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This document explains: how patients are tested and treated, and steps in place to prevent its spread.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Millions invested in eight innovative companies behind lifesaving new medical technology which could destroy liver cancer tumours, detect Alzheimer’s and quickly spot those at risk of stroke
The Yellow Card Biobank will today start investigating a new group of medicines known as Direct Oral Anticoagulants
New features in the NHS App improve patient experience and support elective care recovery, as well as helping reduce ongoing pressure on the health service.
Information for manufacturers of medical devices about reporting adverse incidents and field safety corrective actions to the MHRA.
Advice on writing clear notices and maximising replies to your FSNs.
New tool uses artificial intelligence to assess hospital data and help predict patients at risk of becoming long stayers, with resulting negative implications.
How to use a cost benefit analysis to evaluate your digital health product.
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
Privacy notice for patients participating in surgical site infection surveillance.
How to use a cost effectiveness analysis to evaluate your digital health product.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Actions that trial sponsors should consider to build resilience into clinical trial design
Patients will be given more choice and greater control over their own care, including through the NHS App.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Information about the risks of taking valproate medicines during pregnancy.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.